As reported on BioSpace, Praxis Precision Medicines has received a three-month extension to the U.S. Food and Drug Administration’s review of relutrigine, its investigational therapy for rare genetic forms of developmental epileptic encephalopathy (DEE). The decision moves the agency’s target action date from September 27 to December 27 after the FDA determined that recently submitted analyses constituted a major amendment to the company’s application.
Importantly, Praxis reported that the FDA did not request additional clinical studies and did not identify concerns related to safety, drug manufacturing, or product quality during the review process. The company is seeking approval of relutrigine for patients with DEE associated with mutations in the SCN8A and SCN2A genes.
Analysts at Jefferies characterized the extension as relatively routine and not indicative of regulatory problems. In a note to investors, the firm said the absence of safety, manufacturing, or trial-related issues supports a positive outlook for the program. The analysts also noted that regulators could have issued a complete response letter if significant barriers to approval existed, suggesting the extension alone should not be viewed as a negative signal.
Relutrigine is an oral sodium channel blocker designed to reduce the abnormal electrical activity that contributes to seizures in patients with DEE. The therapy works by limiting persistent sodium current, a mechanism believed to play a central role in seizure generation in these rare neurological disorders.
The drug has shown encouraging clinical results. In late 2025, Praxis announced the early completion of a mid-stage study after an independent data monitoring committee recommended stopping the trial because of strong efficacy findings. Data from the study demonstrated a placebo-adjusted seizure reduction of 53% over 16 weeks, while patients receiving relutrigine experienced substantially more motor seizure-free days compared with those in the control group.
Jefferies described the efficacy data as particularly notable given the limited treatment options currently available for patients with SCN2A- and SCN8A-related DEE. The firm estimates that relutrigine could ultimately surpass $1 billion in peak annual sales within these genetic epilepsy populations alone.
Beyond relutrigine, Praxis continues to expand its rare epilepsy pipeline. The company is developing elsunersen, an antisense oligonucleotide therapy intended to reduce seizures in SCN2A-related DEE. The investigational treatment recently received FDA Breakthrough Therapy designation and is currently being evaluated in the pivotal EMBRAVE3 trial, which remains open for patient enrollment.
While the review extension delays a potential approval decision until the end of the year, investors and analysts appear encouraged that the FDA’s action was procedural rather than driven by concerns about the therapy’s safety or effectiveness.
